Agenus sees positive data for brain cancer vaccine
Agenus Inc. released positive results for its cancer vaccine, which was found in a Phase 2 study to almost double the longevity of patients with recurring glioblastoma multiforme (GBM), a particularly deadly type of brain tumor. The encouraging news comes as the company faces potential delisting from the Nasdaq Stock Market.
The Prophage G-200 vaccine trial showed a median overall survival of 11 months (47.6 weeks), much longer than average survival time of 26 weeks. The drug, which is injected, also showed only mild side effects, said Garo Armen, CEO of Lexington-based Agenus (formerly Antigenics).